Shots:
- Protillion has entered into a multi-target discovery collaboration & license agreement with Merck, integrating Protillion’s Prot-MaP technology with Merck’s global expertise in the discovery of novel therapeutic candidates
- As per the deal, Protillion will receive an undisclosed upfront payment & ~$510M in research, development, & commercial milestone payments for the successful development of multiple therapies
- Prot-MaP platform combines megascale data generation with AI-driven protein design, enabling quantitative analysis of millions of protein variants per run to identify optimized biologics with complex properties, such as pH-dependent sweeping & multi-target specificity, while reducing model overfitting
Ref: Businesswire | Image: Merck & Protillion | Press Release
Related News: Merck Reports FDA Approval of Keytruda/Keytruda QLEX + Welireg in Clear Cell Renal Cell Carcinoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
